Dr Reddy's launches Propofol Injectable Emulsion in US market

Published On 2019-01-25 05:28 GMT | Update On 2019-01-25 05:28 GMT

Propofol Injectable Emulsion is a therapeutic equivalent generic version of Diprivan (Propofol) Injectable Emulsion," the company said in a BSE filing.

New Delhi: Dr Reddy's Laboratories on Thursday announced the launch of Propofol Injectable Emulsion, used for induction of general anaesthesia and sedation in intensive care units, in the US market.

Propofol Injectable Emulsion is a therapeutic equivalent generic version of Diprivan (Propofol) Injectable Emulsion," the company said in a BSE filing.

Dr Reddy's said it uses distribution controls to market Propofol Injectable Emulsion, USP, to prevent any misuse.

"Dr Reddy's will not accept orders from correctional facilities and prison systems whose intended use of the product is to aid in lethal injection. We require the same commitment from our wholesalers and distributors," the company said.

Quoting IMS Health MAT data for twelve months ending in November 2018, Dr Reddy's Laboratories said Diprivan brand and generic had US sales of approximately $310 million.

Also Read: Dr Reddy’s gets four observations from USFDA for Andhra plant

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Dr Reddy's launches Propofol Injectable Emulsion in US market

Similar News